Analyst Ranking Puts Pharma Lab Digital Twins in Focus
IDC MarketScape names Siemens a Leader in life sciences R&D lab technology, citing vendor-side gains that include a 25% cut in physical experiments at GSK.
Updated on Nov. 5, 2026 in Biotech

Siemens was named a Leader in the 2026 IDC MarketScape assessment of worldwide life sciences R&D lab technology and consulting providers. The assessment evaluates vendors on current capabilities and strategy over the next three to five years; this is a vendor evaluation, not a new product launch.
Why it matters
The recognition points to a shift in pharmaceutical research toward digital twins and AI-enabled lab operations, where companies test virtually before committing to physical experiments. GSK and AstraZeneca case studies cited in the assessment show these tools already being applied to vaccine development and tablet manufacturing.
GSK's digital twin reduced physical experiments by 25 per cent, while Siemens' Smart Lab Ecosystem is credited with 31% higher air change rates, 29% faster particle removal and 45% better ventilation efficiency. The figures come from a vendor-side assessment, and the baselines behind the lab-ventilation percentages are not stated in the source.
The players
Siemens
German industrial technology company whose Smart Lab Ecosystem and digital twin portfolio, which includes the 2025 Dotmatics acquisition, target pharmaceutical R&D labs.
GSK
Global pharmaceutical company that used Siemens and Atos to digitalise vaccine development and manufacturing with digital twins and AI.
AstraZeneca
Global pharmaceutical company that worked with Siemens on gPROMS process modelling for tablet manufacturing process design.
IDC MarketScape
Analyst firm assessment framework that evaluates vendors on current capabilities and three-to-five-year strategy in life sciences R&D lab technology.
The details
Siemens' Smart Lab Ecosystem is built to be vendor-agnostic and lets room segments, devices and sensors be composed in a plug-and-play fashion. Its Enterprise Recipe Management approach follows the ISA-88 standard, a widely used industrial specification for batch process control that defines how production recipes are structured and executed. GSK combined AI, SIMATIC SIPAT, TIA Portal and Simcenter to run virtual tests and predictive models fed by real-time sensor data, a digital twin being a software replica of a physical process.
Timeline
Siemens acquired Dotmatics in 2025.
The 2026 IDC MarketScape assessment named Siemens a Leader.
The Tech Race
The IDC MarketScape places Siemens among Leaders in a field where pharmaceutical companies are adopting digital twins and AI-driven lab systems. The positioning is analyst-assessed rather than measured by head-to-head benchmarks, so it signals competitive standing without establishing a performance ranking.
Pharmaceutical R&D teams evaluating lab automation and digital-twin tools can use the assessment as one input when comparing vendors. The source does not state availability dates, pricing or deployment timelines for the Smart Lab Ecosystem.
The takeaway
Watch whether vendor-reported gains such as GSK's 25% reduction in physical experiments hold up as more pharmaceutical companies publish outcomes from digital-twin deployments. The IDC MarketScape three-to-five-year strategy horizon makes future reassessments a useful checkpoint for these claims.
Further reading
For broader context on how digital tools are reshaping drug development, see Biotech.
Source note: This article includes information reported by Manufacturingchemist.


